arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Xenetic Biosciences, Inc.

XBIO
$1.90 ▼ -0.12 (-6.17%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
15 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

Xenetic Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.2M
Dividend Yield —
Revenue Growth 19.0% ↗
Op. Margin -95.2% ↗
ROIC -30.3% ↗
FCF / Share $-1.34 ↗
Trailing P/E —
Price / Book 0.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

15-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.98M
↑ +19.0% —
Net Income Profit after all expenses
$-2.68M
↑ +32.3% —
Operating Margin Operating profit as % of sales
-95.2%
↑ +43.4% 2th
FCF / Share Free cash flow per share
$-1.34
↑ +26.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
3
Returns ↓
20
Cash Quality →
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 15 years · 62 quarters